Intensity Therapeutics, Inc. (INTS)

The immediate outlook is bearish due to a brutal multi-year collapse. The stock has lost over 92% of its value over the last two years, with the most recent annual period seeing a catastrophic 90.8% drop. This isn't a temporary correction; it is a structural implosion where the market has completely rejected the current business model. While the balance sheet currently shows low debt relative to equity, the massive burn rate and negative free cash flow indicate the company is hemorrhaging capital without generating returns. The recent reverse stock split and dilutive direct offerings suggest management is desperate to raise cash, which often signals distress rather than opportunity. With no earnings, negative forward estimates, and a price far below book value driven by fundamental failure rather than a bargain, there is no safe entry point for a long-term holder. The short-term statistical model offers a slight upward lean, but given the low confidence and the depth of the fundamental rot, this is likely just noise in a downtrend. Investors should avoid this security entirely until there is clear evidence of a viable path to profitability or a successful clinical trial that can reverse the decades of value destruction.